hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06322615, orgStudyIdInfo id: MC221001, secondaryIdInfos id: NCI-2024-00538, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-004067, type: OTHER, domain: Mayo Clinic Institutional Review Board, secondaryIdInfos id: MC221001, type: OTHER, domain: Mayo Clinic in Rochester, briefTitle: Acupressure for Reducing Anxiety in Patients Undergoing Chemotherapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-08, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This clinical trial evaluates whether acupressure is helpful to reduce anxiety related to chemotherapy. Anxiety is experienced by many patients with cancer. Anxiety can be related to chemotherapy and may contribute to other symptoms, such as nausea and poor quality of life. Some patients diagnosed with cancer express interest in non-medicinal ways to manage symptoms. Acupressure is a noninvasive intervention that can be used for many different symptoms. Acupressure is well tolerated with minimal reports of adverse reactions, making it a good choice for patients with cancer. This study may help researchers learn whether acupressure is useful for managing anxiety in patients undergoing chemotherapy., conditionsModule conditions: Hematopoietic and Lymphatic System Neoplasm, conditions: Malignant Solid Neoplasm, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Acupressure Therapy, interventions name: Educational Intervention, interventions name: Electronic Health Record Review, interventions name: Questionnaire Administration, outcomesModule primaryOutcomes measure: Number of patients approached about undergoing acupressure intervention (Feasibility), primaryOutcomes measure: Number of patients interested in the initial acupressure intervention in the chemotherapy unit (Feasibility), primaryOutcomes measure: Number of patients interested in the home acupressure intervention (Feasibility), primaryOutcomes measure: Time taken for each nurse-led acupressure intervention in the chemotherapy unit (Feasibility), primaryOutcomes measure: Patient-reported changes in acute anxiety, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Laura S. Rhee, D.O., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06322602, orgStudyIdInfo id: 23-009112, secondaryIdInfos id: NCI-2024-01762, type: REGISTRY, domain: CTRP (Clinical Trials Reporting Program), briefTitle: Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2029-03, completionDateStruct date: 2029-03, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This observational trial evaluates the use of Ommaya reservoir placed during a biopsy to collect biomarkers longitudinally in patients with brain tumor. A biomarker is a measurable indicator of the severity or presence of the disease state. An Ommaya reservoir is a small device that's implanted under the scalp. It allows the doctor to take samples of cerebrospinal fluid (CSF) in the future without doing a spinal tap. The identification of biomarkers in CSF is rapidly emerging as a promising minimally invasive approach for monitoring tumor growth and response to therapy. In the future, these biomarkers may be used to help determine what treatments could be most effective and how well a tumor has responded to prior therapy. Currently, limited long-term access to CSF has made it difficult for studies to learn if collecting CSF at different points in the treatment process is useful. Having an Ommaya reservoir placed during a biopsy may allow for longitudinal biomarker collection in patients with brain tumor., conditionsModule conditions: Brain Neoplasms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Intracranial Catheter Placement, interventions name: Lumbar Puncture, interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, outcomesModule primaryOutcomes measure: Feasibility of Ommaya reservoir placement, secondaryOutcomes measure: Utility of Ommaya reservoir, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Terry C. Burns, M.D., Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06322589, orgStudyIdInfo id: CMUH112-REC3-175, briefTitle: Evaluation of Human Efficacy of SOD Like Super Drink, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: TCI Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To assess the efficacy of SOD like Super Drink on anti-oxidant capacity, immuno regulation and skin for human, conditionsModule conditions: Dermatology, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: SOD like Super Drink, interventions name: placebo drink, outcomesModule primaryOutcomes measure: the volume of skin wrinkles, primaryOutcomes measure: the roughness of skin texture, primaryOutcomes measure: the change of skin elasticity, primaryOutcomes measure: the change of Total Anti-oxidative Capacity (TAC) of blood, primaryOutcomes measure: the change of Superoxide Dismutase (SOD) of blood, primaryOutcomes measure: the change of Glutathione S-transferase (GST) of blood, primaryOutcomes measure: the change of Glutathione (GSH) of blood, primaryOutcomes measure: the change of Malondialdehyde (MDA) of blood, primaryOutcomes measure: the change of immune-related cytokines of blood, secondaryOutcomes measure: the change of skin surface hydration, secondaryOutcomes measure: the change of skin Transepidermal Water Loss (TEWL), secondaryOutcomes measure: the change of Skin Melanin Index, secondaryOutcomes measure: the change of Skin Erythema Index, otherOutcomes measure: The change of liver function biomarkers (AST, ALT) of blood, otherOutcomes measure: The change of renal function biomarkers (creatinine, BUN) of blood, otherOutcomes measure: The change of self-assessment skin condition and immuno condition, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: China Medical University of department of cosmeceutics, status: RECRUITING, city: Taichung City, zip: 406040, country: Taiwan, contacts name: Hsiu-Mei Chiang, Ph.D., role: CONTACT, phone: +886-04-22053366, phoneExt: 5302, email: hmchiang@mail.cmu.edu.tw, contacts name: Ping Lin, role: CONTACT, phone: +886-02-879778111, email: candice.lin@tci-bio.com, geoPoint lat: 24.1469, lon: 120.6839, hasResults: False
protocolSection identificationModule nctId: NCT06322576, orgStudyIdInfo id: IRB00347750, briefTitle: 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2030-12, completionDateStruct date: 2035-12, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, class: OTHER, collaborators name: Adenoid Cystic Carcinoma Research Foundation, collaborators name: Progenics Pharmaceuticals, Inc., descriptionModule briefSummary: This is a single arm trial with one Cohort for people with recurrent or metastatic adenoid cystic carcinoma that cannot be treated with surgery. 10 participants will be enrolled in Cohort 1 at Johns Hopkins and will undergo DCFPyL PET/CT and 177Lu-PSMA dosimetry imaging only (single tracer dose). A feasibility analysis of dosimetry will be performed after meeting the accrual goal of Cohort 1 to determine if the study will proceed into Cohort 2.If Cohort 2 proceeds, based on the dosimetry analysis, the major requirements of the study are to undergo treatment with 177Lu-PNT2002, have bloodwork, physical exams, and imaging done at study-specific time points, and to answer questionnaires. Patients will be in the study for about two years after enrolling., conditionsModule conditions: Adenoid Cystic Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Cohort 1of this study involves only Dosimetry for (10 patients).(Cohort 2 may be added based on dosimetry analysis of Cohort 1. Planned Treatment for would be for 20 patients, single arm)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: 177Lu-PNT2002, outcomesModule primaryOutcomes measure: Absorbed dose in tumor and normal organs, primaryOutcomes measure: Objective response rate (ORR) by RECIST 1.1 measured in patients treated with 177Lu-PSMA for recurrent and metastatic ACC., secondaryOutcomes measure: Stability of Disease: Proportion of patients with Stable Disease, secondaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Duration of Response, secondaryOutcomes measure: Xerostomia questionnaire (XQ) score, secondaryOutcomes measure: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-HN43), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Johns Hopkins Hospital, city: Baltimore, state: Maryland, zip: 21287, country: United States, geoPoint lat: 39.29038, lon: -76.61219, hasResults: False
protocolSection identificationModule nctId: NCT06322563, orgStudyIdInfo id: LTC004-202, briefTitle: Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC. A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial. After completing a 28-day safety assessment, safety will be confirmed before entering the formal trial phase. Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC, conditionsModule conditions: Advanced/Metastatic Colorectal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: LTC004+regorafenib, outcomesModule primaryOutcomes measure: Treatment-Emergent Adverse Events-Safety and Tolerability, primaryOutcomes measure: SAE-Safety and Tolerability, secondaryOutcomes measure: ORR, secondaryOutcomes measure: DCR, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Medical University Cancer Institute and Hospital, city: Tianjin, state: Tianjin, zip: 300060, country: China, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06322550, orgStudyIdInfo id: beingapatient, briefTitle: Influence of Role-expectancy on Patient Reported Outcomes Among Patients With Migraine: a Randomized Clinical Trial, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-10-29, primaryCompletionDateStruct date: 2023-02-01, completionDateStruct date: 2023-02-01, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Universitätsklinikum Hamburg-Eppendorf, class: OTHER, descriptionModule briefSummary: This study was preregistered 2019 under https://osf.io/nczhj. Since JAMA requires a registration with ClinicalTrials.gov, we post-register the study here with the identical informations from OSF (see there)Migraine is frequently associated with motion sickness, vestibular symptoms, and abnormal motion and visual processing. Clinical symptoms and underlying brain mechanisms during self-motion visual stimulation were not yet investigated in this population. Therefore the aim is to investigate the behavioral responses from a visually simulated roller coaster ride of patients with migraine and headache-free controls. In order to verify the effect of response bias, part of the patients with migraine will be informed that the study aims to investigate vestibular disorders instead of headache disorders and that they are invited as healthy controls., conditionsModule conditions: Role-expectancy on Patient Reported Outcomes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Monocenter, randomized, double blind, three-armed clinical trial, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, maskingDescription: Double blind, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 366, type: ACTUAL, armsInterventionsModule interventions name: cover story, outcomesModule primaryOutcomes measure: self-reported vestibular symptoms, secondaryOutcomes measure: differences in motion sickness susceptibility using a standardized motion sickness questionnaire, secondaryOutcomes measure: differences in disability level using a standardized motion sickness questionnaire, secondaryOutcomes measure: differences in headache days per month, secondaryOutcomes measure: differences in headache burden and migraine disability questionnaires, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: UKE, city: Hamburg, zip: 20246, country: Germany, geoPoint lat: 53.57532, lon: 10.01534, hasResults: False
protocolSection identificationModule nctId: NCT06322524, orgStudyIdInfo id: FirstShanxiMU_jsk, briefTitle: Study on Gamma Sensory Flicker for Insomnia, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-01, primaryCompletionDateStruct date: 2022-03-30, completionDateStruct date: 2022-12-30, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Shanxi Medical University, class: OTHER, collaborators name: Shanxi Medical University, descriptionModule briefSummary: This prospective observational study enrolled adult volunteers for a sleep quality research study through a questionnaire survey distributed via a WeChat two-dimensional code from May 2021 to April 2022. Participants were exposed to flicker stimulation through a light and sound device for a duration of 8 weeks with daily monitoring., conditionsModule conditions: Sleep Quality, conditions: Sleep Duration, conditions: Sleep Onset Latency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 37, type: ACTUAL, armsInterventionsModule interventions name: Gamma sensory flicker, outcomesModule primaryOutcomes measure: Treatment adherence rate, primaryOutcomes measure: Patient treatment adherence rate, primaryOutcomes measure: Incidence rate of adverse reaction, primaryOutcomes measure: Differences in sleep duration between the first and eighth weeks, primaryOutcomes measure: Differences in sleep onset latencies between the first and eighth weeks, primaryOutcomes measure: Differences in awakening times between the first and eighth weeks, secondaryOutcomes measure: pre-sleep efficiency., secondaryOutcomes measure: post-sleep efficiency., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yong Xu, city: Taiyuan, state: Shanxi, zip: 030000, country: China, geoPoint lat: 37.86944, lon: 112.56028, hasResults: False
protocolSection identificationModule nctId: NCT06322511, orgStudyIdInfo id: HUS/7626/2023, briefTitle: Dialogical Family Guidance PostDoc Study, acronym: DFG II, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-02, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Tampere University, class: OTHER, descriptionModule briefSummary: This new family intervention, called Dialogical Family Guidance (DFG) is developed to target family needs especially in families with a child with neurodevelopmental disorders. PhD study showed, that this intervention is functioning with this target group. Participants (families) experienced that they got information, guidance to ordinary life and that the DFG-therapists were listening to them and above all, helping with individual problems and questions. DFG include six meetings and professionals need to attend on a 3-day long education before using this intervention., conditionsModule conditions: Family Dynamics, conditions: Family Relations, conditions: Family Support, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Families attending the study Group I: receives Dialogical Family Guidance intervention and they fill questionnaires before and after the intervention.Group II: Families do not receive Dialogical Family Guidance (but belong to the same focus group), primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: Families include both parents and children. Parents fill the questionnaires, but all family members attend on the meetings during the intervention (six meetings)., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Dialogical Family Guidance (DFG), outcomesModule primaryOutcomes measure: FAFHES, secondaryOutcomes measure: DFG-questionnaire, secondaryOutcomes measure: SDQ-p questionnaire (Strengths and difficulties regarding the child), eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 13 Years, stdAges: CHILD, contactsLocationsModule locations facility: Helsinki university hospital, status: RECRUITING, city: Helsinki, zip: 00029, country: Finland, geoPoint lat: 60.16952, lon: 24.93545, hasResults: False
protocolSection identificationModule nctId: NCT06322498, orgStudyIdInfo id: INFLAM.UTERUS-HMO-CTIL, briefTitle: Inflammation Markers in Fluid Aspirate From a Scarred Uterine vs. a Normal Uterine Cavity, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-18, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-21, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Hadassah Medical Organization, class: OTHER, descriptionModule briefSummary: A prospective study that will take place in the hydrosonography clinic, comparing patients with an intact uterus to those who had a caesarean section. Eligible patients will preform a transvaginal ultrasound for evaluation of presence of a niche. After fixation of the transcervical catheter, we will flush 2 ml sterile NaCl 0.9% into the uterine cavity and aspirate the fluid. After collecting all samples, the samples will be snap frozen and stored at -80o C, until they undergo an immunological analysis., conditionsModule conditions: Infertility Due to Nonimplantation, conditions: Infertility Secondary, conditions: Cesarean Section Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Uterine lavage, outcomesModule primaryOutcomes measure: Inflammatory cell population, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Hadassah Medical Organization, status: RECRUITING, city: Jerusalem, country: Israel, contacts name: Hadas Lemberg, PhD, role: CONTACT, phone: 00 972 2 6777572, email: lhadas@hadassah.org.il, contacts name: Chana Adler Lazarovits, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.76904, lon: 35.21633, hasResults: False